Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
CAROLINE E BURNS · BOSTON CHILDREN'S HOSPITAL · 2024 · $621,233 — PROJECT SUMMARY: Hemizygous microdeletions encompassing TBX1 cause 22q11.2 deletion syndrome (22q11.2DS), the most common deletion syndrome in humans. Among a broad spectrum of clinical features that often include craniofacial dysmorphia, congenital heart defects (CHDs) of the outflow tract (OFT), a…
DIANE M CIBRIK · UNIVERSITY OF KANSAS MEDICAL CENTER · 2024 · $310,000 — Project Summary For patients with end-stage renal disease, kidney transplantation is the best clinical treatment. While this procedure improves kidney function and survival in these patients, kidney transplantation is also associated with an increase in cardiometabolic disease, which includes gluco…
Jamil Azzi · BRIGHAM AND WOMEN'S HOSPITAL · 2024 · $440,383 — Inflammation negatively affects Tregs stability and suppressive function, impairs the induction of solid organ transplant tolerance and enhances acute and chronic rejection, leading to worse recipients’ long-term outcomes. Insights into key inflammatory pathways that suppress Tregs during allo-immun…
Andrew Gunderson · OHIO STATE UNIVERSITY · 2024 · $404,798 — PROJECT SUMMARY Tertiary lymphoid structures (TLS) are T and B lymphocytes in aggregation with antigen presenting cells, fibroblasts, and high endothelial venules observed in some chronically inflamed tissues. TLS formation in tumors of cancer patients is associated with improved adaptive immune fun…
Kristina H Lewis · HARVARD PILGRIM HEALTH CARE, INC. · 2024 · $769,985 — PROJECT SUMMARY/ABSTRACT Over 40% of US adults have obesity, many with weight-related complications such as hypertension and diabetes. Current clinical guidelines suggest lifestyle change as the first-line obesity treatment approach, but this does not produce sustained clinically-significant weight …
Anthony Charles Faber · VIRGINIA COMMONWEALTH UNIVERSITY · 2024 · $434,312 — Project Summary: High-risk neuroblastoma (NB) is responsible for ~15% of pediatric cancer-related deaths, with nearly half of these characterized by MYCN amplification. The addition of anti-GD2 antibodies and retinoids to maintenance therapy has improved the outcomes of these patients, but still mor…
MEI LIU · UNIVERSITY OF FLORIDA · 2024 · $300,243 — (PLEASE KEEP IN WORD, DO NOT PDF) Acute Kidney Injury (AKI) is a life-threatening clinical syndrome prevalent in hospitalized patients (10-15% affected), especially among critically ill patients (>50% affected). AKI patients are 6.5-fold more likely to die in the hospital and at much higher risk for…
Benjamin Y. Xu · UNIVERSITY OF SOUTHERN CALIFORNIA · 2024 · $468,430 — Abstract Glaucoma is the leading cause of irreversible blindness worldwide. Angle closure, which impairs aqueous humor outflow and leads to elevated intraocular pressure (IOP), is the primary cause of 23 million or nearly one third of all glaucoma cases. Primary angle closure glaucoma (PACG) is thre…
DAVID A. BRENNER · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2024 · $725,478 — Project Summary Pancreatic ductal adenocarcinoma (PDAC) is characterized by extensive desmoplasia, resulting in occupancy of most of the tumor mass by a dense stroma consisting of fibroblasts, macrophages, and extracellular matrix (ECM). Fibrillar collagens, such as type I collagen (Col I), are majo…
Seth Blackshaw · JOHNS HOPKINS UNIVERSITY · 2024 · $409,375 — Project Summary GABAergic neurons of the dorsolateral hypothalamus play an essential role in both the regulating the sleep/wake cycle, but little is known about the molecular mechanisms that control their development. We have recently found that the LIM homeodomain transcription factor Lhx6 is nece…
Roland W. Herzog · INDIANA UNIVERSITY INDIANAPOLIS · 2024 · $2,492,072 — PROJECT SUMMARY ABSTRACT Gene therapy for the X-linked bleeding disorder hemophilia holds much promise to accomplish a lasting cure. Four clinical trials utilizing adeno-associated viral (AAV) gene transfer to the livers of males with severe hemophilia are currently being investigated in multiple Ph…
Alison M El Ayadi · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2024 · $334,728 — PROJECT SUMMARY Obstetric fistula is a traumatic maternal morbidity resulting in severe urinary incontinence that increases stigma and reduces quality of life. The two million women with fistula, most in sub-Saharan Africa, face substantial multi- level barriers to surgical repair. Women need an acc…
Harris R Perlman · NORTHWESTERN UNIVERSITY AT CHICAGO · 2024 · $664,268 — Project Summary Macrophages are critical to the pathogenesis of rheumatoid arthritis (RA), but several distinct macrophage subpopulations co-exist in the synovium of joints. In steady-state, tissue-resident macrophages contribute to joint integrity and are required for tissue homeostasis. While incr…
Monika Kumari Goyal · CHILDREN'S RESEARCH INSTITUTE · 2024 · $695,471 — Project Abstract Adolescents account for nearly half of all new sexually transmitted infection (STI) cases annually, and of those, non-Hispanic Black and Hispanic youth are disproportionately affected. These disparities are attributed, in part, to differential access to and routine use of quality he…
KANG KIM · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2024 · $758,510 — PROJECT SUMMARY Acute coronary syndromes and strokes together constitute a leading cause of morbidity and mortality in the United States and Europe, approximately 80% of which are caused by atherosclerotic plaque (AP) rupture. Over the past decade, extensive efforts have been made to identify a rup…
JINDRICH H. KOPECEK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · 2024 · $331,402 — Rituximab (RTX) and other anti-CD20 antibodies (ofatumumab and obinutuzumab (OBN)) dramatically improved treatment of Non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Alone or in combination with chemotherapy (e.g. R-CHOP, a combination with cyclophosphamide, doxorubicin, vincristi…
ALBERTO L VAZQUEZ · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2024 · $515,456 — PROJECT SUMMARY/ABSTRACT Neuronal activity actively modulates local cerebral vasculature. This neuro-vascular interaction is the foundation of imaging studies of human brain function in health and disease. These studies are routinely performed while subjects perform tasks (evoked activity) or lie re…
Aimee Marie Crago · SLOAN-KETTERING INST CAN RESEARCH · 2024 · $530,202 — Desmoid-type fibromatosis is a mesenchymal tumor that does not progress to high-grade disease or metastasize. Surgery was the standard treatment for desmoids, but in patients with extensive disease, surgery can lead to complications as morbid as the tumors themselves, and ~30% of patients have local…
Robert Desimone · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2024 · $225,900 — PROJECT SUMMARY/ABSTRACT The ability to genetically modify the mouse genome has revolutionized biomedical research. However, its impact on our understanding of brain disorders is limited partially due to the inherent differences in the structure and physiology of the brain between rodents and human…
David Beck · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2024 · $606,951 — Project Summary (<30 lines): VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a newly identified inflammatory and hematologic disease caused by somatic mutations in UBA1. Individuals with UBA1 mutations have clinical manifestations similar to well-established rheumatic di…